⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28629514 | 0.78 | CA14 (0.31) | — | |
| SCHEMBL12483135 | 0.77 | HDAC1 (0.31) | — | |
| SCHEMBL6813444 | 0.77 | HDAC1 (0.31) | — | |
| SCHEMBL2338927 | 0.77 | HDAC1 (0.30) | — | |
| SCHEMBL2338932 | 0.77 | HDAC1 (0.30) | — | |
| SCHEMBL3928699 | 0.73 | HDAC1 (0.30) | — | |
| SCHEMBL6403514 | 0.71 | — | — | |
| SCHEMBL28296147 | 0.71 | CA14 (0.37) | — | |
| SCHEMBL182866 | 0.69 | F2 (0.47) | — | |
| SCHEMBL1535717 | 0.69 | F2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2018-12-06 | — | — | US | disclosed |
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2016-10-13 | — | — | US | disclosed |
| US-9434753-B2 | Modified creatine compounds | GENCIA CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-9345739-B2 | Methods and compositions for the treatment of proteinuric diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150005258-A1 | Modified Creatine Compounds | Genci Corporation (US) | 2015-01-01 | — | — | US | disclosed |
| EP-2730282-A1 | Methods and compositions for the treatment of proteinuric diseases | The General Hospital Corporation (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION | 2010-11-25 | — | — | US | disclosed |
| WO-2009061448-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2009-08-13 | — | — | WO | disclosed |
| EP-1575900-A4 | N-METHYL AMINO ACIDS | UBIQUITOUS TECHNOLOGIES PTY LT (AU) | 2007-02-21 | — | — | EP | disclosed |
| US-6974828-B2 | Propanoic acid derivatives as intergrin receptor antagonists | PHARMACIA ITALIA S.P.A. (IT) | 2005-12-13 | — | — | US | disclosed |
| US-20050245432-A1 | N-methyl amino acids | UBIQUITOUS TECHNOLOGIES PTY. LTD. (AU) | 2005-11-03 | — | — | US | disclosed |
| EP-1575900-A1 | N-METHYL AMINO ACIDS | UBIQUITOUS TECHNOLOGIES PTY LTD (AU) | 2005-09-21 | — | — | EP | disclosed |
| EP-1282602-B1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA ITALIA SPA (IT) | 2005-09-21 | — | — | EP | disclosed |
| EP-1383739-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2004-01-28 | — | — | EP | disclosed |
| WO-2004007427-A1 | N-METHYL AMINO ACIDS | UBIQUITOUS TECHNOLOGIES PTY LTD (AU) | 2004-01-22 | — | — | WO | disclosed |
| US-20030144311-A1 | Propanoic acid derivatives as intergrin receptor antagonists | PHARMACIA ITALIA S.P.A. (IT) | 2003-07-31 | — | — | US | disclosed |
| EP-1282602-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Italia S.p.A. (IT) | 2003-02-12 | — | — | EP | disclosed |
| WO-2002085844-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | disclosed |
| WO-2001087840-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA ITALIA S.P.A. (IT) | 2001-11-22 | — | — | WO | disclosed |